Kura Oncology Reports Second Quarter 2022 Financial Results
Kura Oncology reported its Q2 2022 financial results and highlighted significant advancements in its clinical programs. The company identified a recommended Phase 2 dose for ziftomenib, pending FDA review, and enrolled an additional 18 patients in the KOMET-001 trial targeting acute myeloid leukemia. They observed preliminary efficacy in the KURRENT-HN trial of tipifarnib with alpelisib. Kura holds $450 million in cash and equivalents, expected to fund operations through 2024.
- Identified recommended Phase 2 dose for ziftomenib, pending FDA review.
- Additional 18 patients enrolled in KOMET-001 trial for AML.
- Preliminary activity observed in KURRENT-HN trial for tipifarnib plus alpelisib.
- Strong cash position with $450 million, funding operations through 2024.
- Net loss for Q2 2022 increased to $34.8 million from $33.7 million YoY.
- R&D expenses rose to $24.3 million, reflecting increased clinical trial costs.
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –
– Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML –
– Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort –
–
– Management to host webcast and conference call today at 4:30 p.m. ET –
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and provided a corporate update.
“We continue to advance our programs toward a series of important milestones later this year,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “For our menin inhibitor program, we have nearly completed our assessment of patients in the Phase 1b expansion cohorts of our KOMET-001 trial required to identify a recommended Phase 2 dose and remain enthusiastic about the potential for ziftomenib in the treatment of acute leukemias. We look forward to sharing the recommended Phase 2 dose later this year, pending FDA review, along with topline data from the Phase 1b study, followed by a more complete dataset at a medical meeting in the fourth quarter.”
“For our farnesyl transferase inhibitor (FTI) program,” Dr. Wilson continued, “we are encouraged by the preliminary safety and tolerability of tipifarnib in combination with the PI3Kα inhibitor, alpelisib, as well as early evidence of clinical activity observed in our KURRENT-HN trial. Meanwhile, we remain on track to initiate our KURRENT-LUNG trial of tipifarnib in combination with the EGFR inhibitor, osimertinib, later this quarter and submit an investigational new drug (IND) application for our next-generation FTI, KO-2806, by year end. And we approach these milestones from a position of financial strength, with
Recent Highlights
- Recommended Phase 2 dose for ziftomenib identified, pending FDA review – In May 2022, Kura announced that it completed enrollment of the 24 patients in the Phase 1b expansion cohorts of the KOMET-001 trial required to identify a recommended Phase 2 dose for ziftomenib. The two Phase 1b expansion cohorts – 200 mg and 600 mg – are each comprised of patients with NPM1-mutant or KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML). The Company has nearly completed its assessment of the patients for efficacy, safety and tolerability as well as pharmacokinetics and exposure, and believes it has identified a recommended Phase 2 dose for ziftomenib, pending FDA review.
- Additional 18 patients enrolled in KOMET-001 trial – Since May 2022, Kura has enrolled an additional 18 patients with NPM1-mutant or KMT2A-rearranged relapsed/refractory AML in the Phase 1b expansion cohorts as the Company prepares to transition into the Phase 2 registration-directed portion of the KOMET-001 trial and initiate a series of combination studies in the relapsed and frontline settings, pending determination of the recommended Phase 2 dose in consultation with the FDA. Kura believes data from all patients treated at the recommended Phase 2 dose will have the potential to contribute to the registrational patient population.
- Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib –Enrollment continues in the Phase 1/2 KURRENT-HN trial of tipifarnib in combination with the PI3Kα inhibitor, alpelisib, in patients with head and neck squamous cell carcinoma (HNSCC). The initial cohort includes patients who have PIK3CA-dependent HNSCC. In addition, the first patient has been dosed in a second cohort of patients with HRAS overexpression. Kura is encouraged by the preliminary safety and tolerability of the combination thus far, as well as early evidence of clinical activity. The Company believes the combination with alpelisib has the potential to increase the total addressable population for tipifarnib to as much as
50% of patients with HNSCC. - KURRENT-LUNG trial of tipifarnib plus osimertinib to initiate this quarter – Kura is preparing to initiate a Phase 1 KURRENT-LUNG trial of tipifarnib in combination with osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC) later this quarter. Preclinical data, generated through a collaboration with INSERM (the French National Institute of Health and Medical Research), support the potential of tipifarnib to prevent emergence of resistance to osimertinib in EGFR-mutant NSCLC. The Company intends to perform initial clinical evaluation with tipifarnib while advancing its next-generation FTI, KO-2806, through IND-enabling studies.
Financial Results
- Research and development expenses for the second quarter of 2022 were
$24.3 million , compared to$21.1 million for the second quarter of 2021. The increase in R&D expenses was primarily due to increases in clinical trial costs related to the ziftomenib program and personnel costs. - General and administrative expenses for the second quarter of 2022 were
$11.1 million , compared to$12.6 million for the second quarter of 2021. The decrease in G&A expenses was primarily due to decreases in personnel costs and professional
fees. - Net loss for the second quarter of 2022 was
$34.8 million , compared to a net loss of$33.7 million for the second quarter of 2021.This included non-cash share-based compensation expense of$6.5 million , compared to$6.0 million for the same period in 2021. - Cash, cash equivalents and short-term investments totaled
$450.3 million as of June 30, 2022, compared with$518.0 million as of December 31, 2021. Based on its operating plan, management expects that cash, cash equivalents and short-term investments will fund current operations through 2024.
2022 Milestones
- Determine the recommended Phase 2 dose for ziftomenib in consultation with the FDA and report topline data from the Phase 1b study later this year.
- Present updated data from KOMET-001 at a medical meeting in the fourth quarter.
- Initiate the KURRENT-LUNG trial of tipifarnib and osimertinib in the third quarter.
- Submit an IND application for KO-2806 in the fourth quarter.
Conference Call and Webcast
Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT today, August 3, 2022, to discuss the financial results for the second quarter 2022 and to provide a corporate update. The live call may be accessed by dialing (888) 882-4478 for domestic callers and (323) 794-2590 for international callers and entering the conference ID: 8696904. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated NSCLC. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura’s product candidates, ziftomenib, tipifarnib and KO-2806, progress and expected timing of Kura’s drug development programs and clinical trials and submission of regulatory filings, the presentation of data from clinical trials, plans regarding regulatory filings and future clinical trials, the regulatory approval path for tipifarnib, the strength of Kura’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, including the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2022, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| KURA ONCOLOGY, INC. | ||||||||||||
| Statements of Operations Data | ||||||||||||
| (unaudited) | ||||||||||||
| (in thousands, except per share data) | ||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Operating Expenses: | ||||||||||||
| Research and development | $ | 24,258 | $ | 21,074 | $ | 45,171 | $ | 41,398 | ||||
| General and administrative | 11,075 | 12,573 | 22,944 | 23,145 | ||||||||
| Total operating expenses | 35,333 | 33,647 | 68,115 | 64,543 | ||||||||
| Other income (expense), net | 564 | (16 | ) | 893 | 186 | |||||||
| Net loss | $ | (34,769 | ) | $ | (33,663 | ) | $ | (67,222 | ) | $ | (64,357 | ) |
| Net loss per share, basic and diluted | $ | (0.52 | ) | $ | (0.51 | ) | $ | (1.01 | ) | $ | (0.97 | ) |
| Weighted average number of shares used in computing net loss per share, basic and diluted | 66,672 | 66,282 | 66,639 | 66,250 | ||||||||
| KURA ONCOLOGY, INC. | ||||||
| Balance Sheet Data | ||||||
| (unaudited) | ||||||
| (in thousands) | ||||||
| June 30, | December 31, | |||||
| 2022 | 2021 | |||||
| Cash, cash equivalents and short-term investments | $ | 450,258 | $ | 517,960 | ||
| Working capital | 441,913 | 499,834 | ||||
| Total assets | 471,425 | 534,051 | ||||
| Long-term liabilities | 4,061 | 4,987 | ||||
| Accumulated deficit | (500,190 | ) | (432,968 | ) | ||
| Stockholders’ equity | 449,491 | 506,609 | ||||
Contacts
Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com
FAQ
What is Kura Oncology's financial loss in Q2 2022?
How much cash does Kura Oncology have for operations?
What are the key clinical trial updates from Kura Oncology?
What is the status of Kura Oncology's drug candidate ziftomenib?
